From lab to bedside: Emerging clinical applications of thymosin α1

Expert Opinion on Biological Therapy

Volumn 9, Issue 5, 2009, Pages 593-608

  Goldstein, Allan L ^a   Goldstein, Adam L ^b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Biological response modifiers; Cancer; Immune modulation; Infectious diseases; T cells; Thymosin 1

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BIOLOGICAL RESPONSE MODIFIER; DACARBAZINE; DOXORUBICIN; HEPATITIS VACCINE; INFLUENZA VACCINE; INTERFERON; INTERLEUKIN 2; LAMIVUDINE; PLACEBO; PROTEINASE INHIBITOR; SULPERAZON; THYMOSIN ALPHA1; THYMOSIN FRACTION 5; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADJUVANT THERAPY; ADULT RESPIRATORY DISTRESS SYNDROME; AGING; ANTIBODY TITER; ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BREAST CANCER; CHEMOEMBOLIZATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; DIGEORGE SYNDROME; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENTIATION; ENDEMIC DISEASE; HEPATITIS; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INFLUENZA; LIVER CELL CARCINOMA; LIVER RESECTION; LUNG CANCER; LUNG INFECTION; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MYCOBACTERIOSIS; MYCOSIS; NONHUMAN; PERITONITIS; PLEIOTROPY; PSEUDOMONAS PNEUMONIA; REVIEW; SENESCENCE; SEPSIS; SEVERE ACUTE RESPIRATORY SYNDROME; SIGNAL TRANSDUCTION; VIRUS HEPATITIS; VIRUS INFECTION;

ANIMALS; HEPATITIS B; HEPATITIS C, CHRONIC; HUMANS; IMMUNE SYSTEM DISEASES; POINT-OF-CARE SYSTEMS; TECHNOLOGY, PHARMACEUTICAL; THYMOSIN;

CYTOMEGALOVIRUS; HEPATITIS C VIRUS;

EID: 67649094526     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590902911412     Document Type: Review

References (123)

1. Talmadge JE, Fidler IJ, Oldham RK. The NCI preclinical screen of biological response modifiers. Behring Inst Mitt 1984;74:189-194
2. Rusthoven JJ. Biological response modifiers and infectious diseases: actual and potential therapeutic agents. Int J Antimicrob Agents 1994;3(4):223-243 (Pubitemid 2042325)
3. Garaci E, Pica F, Rasi G, et al. Combination therapy with BRMs in cancer and infectious diseases. Mech Ageing Dev 1997;96(103):103-116 (Pubitemid 27279820)
4. Louie SG, Park B, Yoon H. Biological response modifiers in the management of rheumatoid arthritis. Am J Health Syst Pharm 2003;60(4):346-355 (Pubitemid 36749033)
5. Goldstein AL, Badamchian M. Thymosins: chemistry and biological properties in health and disease. Expert Opin Biol Ther 2004;4:559-573 (Pubitemid 38480555)
6. Goldstein AL, Garaci E. Combination therapies: biological response modifiers in the treatment of cancer and infectious diseases. New York: Plenum Press, 1992
7. Garaci E, Goldstein AL. Combination therapies II: biological response modifiers in the treatment of cancer and infectious diseases. New York: Plenum Press, 1993
8. Goldstein AL, Slater FD, White A. Preparation, assay and partial purification of a thymic lymphocytopoietic factor (thymosin). Proc Natl Acad Sci USA 1966;56:1010-1017
9. Miller JFAP. Immunological function of the thymus. Lancet 1961;2:748-749
10. Good RA, Dalmasso C, Martinez C, et al. The role of the thymus in development of immunologic capacity in rabbits and mice. J Exp Med 1962;116:773-796
11. White A, Goldstein AL. Is the thymus an endocrine gland? Old problem, new data. Prespect Biol Med 1968;11:475-489
12. Hooper JA, McDaniel MC, Thurman GB, et al. The purification and properties of ovine thymosin. Ann NY Acad Sci 1975;249:125-144
13. Goldstein AL, Cohen GH, Rossio JH, et al. Use of thymosin in the treatment of primary immunodeficiency diseases and cancer. Med Clin North Am 1976;60:591-606
14. Wara DW, Goldstein AL, Doyle N, et al. Thymosin activity in patients with cellular immunodeficiency. N Engl J Med 1975;292:70-74
15. Barrett DJ, Wara DW, Ammann AJ, et al. Thymosin therapy in the DiGeorge syndrome. J Pediatr 1980;97:66-71 (Pubitemid 10033765)
16. Goldstein AL, Low TLK, McAdoo M, et al. Thymosin α1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci 1977;74:725-729 (Pubitemid 8038798)
17. Low TLK, Thurman GB, McAdoo M, et al. The chemistry and biology of thymosin. I. Isolation, characterization and biological activities of thymosin α1 and polypeptide β1 from calf thymus. J Biol Chem 1979;254:981-986
18. Low TLK, Goldstein AL. The chemistry and biology of thymosin. II. Amino acid sequence analysis of thymosin α1 and polypeptide β1. J Biol Chem 1979;254:987-995 (Pubitemid 9145947)
19. Wang SS, Makofske R, Bach A, et al. Automated synthesis of thymosin α1. Intern J Peptide Protein Res 1980;15:1-4
20. Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med 2005;11:421-429 (Pubitemid 41254045)
21. Haritos AA, Goodall GJ, Horecker BL. Prothymosin α: isolation and properties of the major immunoreactive form of thymosin α1 in rat thymus. Proc Natl Acad Sci USA 1984;81:1008-1011
22. Goldstein AL, Garaci E, editors, Thymosins in Health and Disease. New York: Ann NY Acad Sci 2007;1112
23. Wetzel R, Heyneker HL, Goeddel DV, et al. Production of biologically active Nα-desacetyl thymosin α1 in Escherichia coli through expression of a chemically synthesized gene. Biochemistry 1980;19:6096-6104 (Pubitemid 11134694)
24. Romani L, Bistoni F, Gaziano R, et al. Thymosin α1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 2004;103:4232-4239 (Pubitemid 38685368)
25. Giuliani C, Napolitano G, Mastino A, et al. Thymosin α1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur J Immunol 2000;30:778-786 (Pubitemid 30216249)
26. Sztein M, Serrate S, Goldstein AL. Modulation of interleukin-2 receptor expression on normal human lymphocytes by thymic hormones. Proc Natl Acad Sci 1986;83:6107-6111 (Pubitemid 16000662)
27. Peng X, Zhang P, Wang X, et al. Signaling pathways leading to the activation of IKK and MAPK by thymosin α1. Ann NY Acad Sci 2007;1112:339-350 (Pubitemid 47598664)
28. Calvo JR, Goberna R, Guerrero JM. Interaction of thymic peptide thymosin α1 with vasoactive intestinal peptide (VIP) receptors. Biosci Rep 1986;6:727-733 (Pubitemid 17193890)
29. Nguyen T, Scheving L. Thymosin α1: amino acid homology with peptide T from the human immunodeficiency virus envelope. Biochem Biophys Res Commun 1987;145:884-887 (Pubitemid 17093522)
30. Sarin PR, Sun DK, Thornton AH, et al. Neutralization of HTLV-III/LAV replication by antiserum to thymosin α1. Science 1986;232:1135-1137 (Pubitemid 16050802)
31. Kahn JO, Stites DP, Scillian J, et al. A Phase-I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue subunit vaccine in seronegative subjects. AIDS Res Hum Retroviruses 1992;8:1321-1325
32. Zav'yalov VP, Navolotskaya EV, Avramov VM, et al. The octapeptide corresponding to the region of the highest homology between α-interferon and thymosin α1 effectively competes with both cytokines for common high-affinity receptors on murine thymocytes. FEBS Lett 1991;278:187-189
33. Ahmed A, Wong DM, Thurman GB, et al. T-lymphocyte maturation: cell surface markers and immune functions induced by T-lymphocyte cell-free products and thymosin polypeptides. Ann NY Acad Sci 1979;332:81-94
34. Ho AD, Ma DD, Price G, et al. Biochemical and immunological differentiation of human thymocytes induced by thymic hormones. Immunology 1983;50:471-476
35. Ho AD, Stehle B, Dietz G, et al. Terminal differentiation of cord blood lymphocytes induced by thymosin fraction 5 and thymosin α1. Scand J Immunol 1985;21:221-225 (Pubitemid 15108048)
36. Hsia J, Sarin N, Oliver JH, et al. Aspirin and thymosin increase interleukin-2 and interferon-gamma production by human peripheral blood lymphocytes. Immunopharmacology 1989;17:167-173 (Pubitemid 19151489)
37. Thurman GB, Seals C, Low TLK, et al. Restorative effects of thymosin polypeptides on purified protein derivative-dependent migration inhibition factor production by the peripheral blood lymphocytes of adult thymectomized guinea pigs. J Biol Resp Mod 1984;3:160-173 (Pubitemid 14114013)
38. Knutsen AP, Freeman JJ, Mueller KR, et al. Thymosin α1 stimulates maturation of CD 34+ stem cells into CD3+4+ cells in an in vitro thymic epithelia organ coculture model. Int J Immunopharmacol 1999;21:15-16
39. DiFrancesco P, Pica F, Gaziano R, et al. In vivo recovery of natural killer cell activity by the association of thymosin α1 and cytokines during cocaine administration. Med Sci Res 1994;22:41-42
40. Serrate S, Schulof R, Leondaridis L, et al. Modulation of human natural killer cell cytotoxic activity, lymphokine production, and interleukin-2 receptor expression by thymic hormones. J Immunol 1987;139:2338-2343 (Pubitemid 17152131)
41. Sztein M, Serrate S. Characterization of the immunoregulatory properties of thymosin α1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes. Int J Immunopharmcol 1989;11:789-800 (Pubitemid 19252366)
42. Hadden JW, Saha A, Sosa M, et al. Immunotherapy with natural interleukins and/or thymosin α1 potently augments T-lymphocyte responses of hydrocortisone-treatment aged mice. Int J Immunopharmacol 1995;17:821-828
43. Leichtling KD, Serrate SA, Sztein MB. Thymosin α1 modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes. Int J Immunopharmacol 1990;12:19-29 (Pubitemid 20034207)
44. Favalli C, Mastino A, Jezzi T, et al. Synergistic effect of thymosin α1 and α β-interferon on NK activity in tumorbearing mice. Int J Immunopharmacol 1989;11:443-450 (Pubitemid 19224100)
45. Mastino A, Favalli C, Grelli S, et al. Combination therapy with thymosin α1 potentiates the antitumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice. Int J Cancer 1992;50:493-499
46. Garaci E, Pica F, Sinibaldi-Vallebona P, et al. Thymosin α1 in combination with cytokines and chemotherapy for the treatment of cancer. Int Immunopharmacol 2003;3:1145-1150 (Pubitemid 36833274)
47. Garaci E, Pica F, Rasi G, et al. Thymosin α1 in the treatment of cancer: from basic research to clinical application. Int J Immunopharmacol 2000;22:1067-1076 (Pubitemid 32012965)
48. Rasi G, Pierimachi P, Sinibaldi-Vallebona P, et al. Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma. Int Imunopharmacol 2003;3:1169-1176 (Pubitemid 36833275)
49. Garaci E, Mastino A, Favalli C. Enhanced immune response and antitumor immunity with combinations of biological response modifiers. Bulletin NY Acad Med 1989;65:111-119 (Pubitemid 19065032)
50. Loggi E, Gramenzi A, Margotti M, et al. In vitro effect of thymosin α1 and interferon-alpha on TH1 and TH2 cells and cytokine synthesis in patients with eAg-negative chronic hepatitis B. J Viral Hepatitis 2008;15:442-448
51. Garaci E, Rocchi G, Perroni L, et al. Combination treatment with zidovudine, thymosin α1 and interferon-α in human immunodeficiency virus infection. Int J Clin Lab Res 1994;24:23-28
52. Favalli C, Jezzi T, Mastino A, et al. Modulation of natural killer activity by thymosin α1 and interferon. Cancer Immunol Immunother 1985;20:189-192 (Pubitemid 16250227)
53. Garaci E, Pica F, Mastino A, et al. Antitumor effect of thymosin α1 interleukin-2 or thymosin α1/interferon αβ following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells. J Immunother Emphasis Tumor Immunol 1993;13:7-17 (Pubitemid 23011930)
54. Kageshita T, Hirai S, Ono T, et al. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 1999;154:745-754 (Pubitemid 29122593)
55. Shrivastava P, Singh SM, Singh N. Effect of thymosin α1 on the antitumor activity of tumor-associated macrophage-derived dendritic cells. J Biomed Sci 2004;11:623-630 (Pubitemid 39179127)
56. Clement CG, Mihm MC Jr, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase primary cutaneous melanoma. Cancer 1996;77:1303-1310 (Pubitemid 26102328)
57. Haanen JB, Baars A, Gomez R, et al. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother 2006;55:451-458 (Pubitemid 43076897)
58. Zhang P, Chan J, Dragoi AM, et al. Activation of IKK by thymosin α1 requires the TRAF6 signaling pathway. EMBO Rep 2005;6:531-537 (Pubitemid 40973961)
59. Baumann CA, Badamchian M, Goldstein AL. Thymosin α1 antagonizes dexamethasone and CD3-induced apoptosis of CD4+CD8+ thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways. Mech Age Develop 1997;94:85-101 (Pubitemid 27216098)
60. Rasi G, Silecchia G, Sinibaldi-Vallebona P, et al. Anti-tumor effect of combined treatment with thymosin α1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. Int J Cancer 1994;57:701-705 (Pubitemid 24201363)
61. Pica F, Fraschetti M, Matteucci C, et al. High doses of thymosin α1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma. Anti Res 1998;18:3571-3578 (Pubitemid 28546492)
62. Silecchia G, Guarino E, Sinibaldi-Vallebona P, et al. Efficacy of repeated cycles of chemo-immunotherapy with thymosin α1 interleukin-2 after intraperitoneal 5-fluorouracil delivery. Cancer Immunol Immunother 1999;48:172-178 (Pubitemid 29333860)
63. Romani L, Bistoni F, Perruccio K, et al. Thymosin α1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood 2006;108:2265-2274 (Pubitemid 44497509)
64. Tuthill C. Issues in pharmaceutical development of thymosin α1 in studies through marketing. Ann NY Acad Sci 2007;1112:351-356 (Pubitemid 47598648)
65. Shen S, Josselson J, McRoy C, et al. Effects of thymosin α1 on peripheral T-cell and Hepatovax-B vaccination in previously non-responsive hemodialysis patients. Hepatology 1987;7:11-20
66. Shen S, Corteza QB, Josselson J. Age dependent enhancement of influenza vaccine responses by thymosin in chronic hemodialysis patients. In: Goldstein AL, editor, Biomedical advances in aging. New York: Plenum Press, 1990. p. 523-530
67. Burchardi H, Schneider P. Economic Aspects of severe sepsis. a review of intensive care unit costs, cost of illness, and cost of effective therapy. Pharmacoeconomics 2004;22:793-813 (Pubitemid 39158998)
68. Huang SW, Guan XD, Chen J, et al. Clinical study and long-term evaluation of immunomodulation therapy on trauma, severe sepsis, and multiple organ dysfunction syndrome patients. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2006;18(11):653-656 (Pubitemid 44823436)
69. Lin HY. Clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with Ulinastatin and Maipuxin. Zhonghua Yi Xue Za Zhi 2007;87:451-457
70. Chen J. Effects of thymosin α1 on cell immunity function in patients with septic shock. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2007;19:153-155 (Pubitemid 46534178)
71. Zhang Y, Chen H, Li YM, et al. Thymosin α1- and ulinastatin-based immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria. J Infect Dis 2008;198:723-730
72. Li Y, Chen H, Li X, et al. A new immunomodulatory therapy for severe sepsis: ulinastatin plus thymosin α1. J Intensive Care Med 2008;10:1-7
73. Yu Y, Tian JH, Yang KH, et al. Evaluation of the efficacy of thymosin α1 in the treatment of sepsis: a systemic review. Zhongguo Wei Zhong Bing Ji Jiu Xue 2009;21:21-24
74. Zhao M-Y, Cao Y, Fei D, et al. Influence of thymosin α1 on the cellular immune function in patients with severe sepsis. Chin J Crit Care Med 2007;27(3):206-208
75. Rosenberg AL, Dechert RE, Park PK, et al. Review of a large clinical series: association of cumulative fluid balance on outcome of acute lung injury: a retrospective review of the ARDS net tidal volume study cohort. J Intensive Care Med 2009;24:35-46
76. Sun Q, Liu Z-H, Chen J, et al. An aggressive systematic strategy for acute respiratory distress syndrome caused by severe pneumonia after renal transplantation. Eur Soc Transpl Int 2006;19:110-116
77. Ji S-M, Li L-S, Sun Q-Q, et al. Immunoregulation of thymosin α1 treatment of cytomegalovirus infection accompanied with acute respiratory distress syndrome after renal transplantation. Transpl Proc 2007;39:115-119 (Pubitemid 46175928)
78. Marra MA, Jones SJ, Astell CR, et al. The genome sequence of the SARS-associated coronavirus. Science 2003;300:1399-1404 (Pubitemid 36638153)
79. Gao ZC, Zhu JH, Sun Y, et al. Clinical investigation of outbreak of nosocomial severe acute respiratory syndrome. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2003;15(6):332-335
80. Schulof RS, Simon GL, Sztein MB, et al. Phase I/II trial of thymosin fraction 5 and thymosin α1 in HTLV-III-seropositive subjects. J Biol Resp Mod 1986;5:429-443 (Pubitemid 17199894)
81. Garaci E, Rocchi G, Perroni L, et al. Combination treatment with zidovudine, thymosin α1 and interferon-α in human immunodeficiency virus infection. Int J Clin Lab Res 1994;24:23-28
82. Chadwick D, Pido-Lopez J, Pires A, et al. A pilot study of the safety and efficacy of thymosin α1 in augmenting immune reconstruction in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy. Clin Exp Immunol 2003;134:447-481 (Pubitemid 37542088)
83. Feltman H, Schulert G, Khan S, et al. Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology 2001;147:2659-2669 (Pubitemid 32976307)
84. Huang D-P, Yang M, Peng W-P, et al. Prevention and management of lung infections with thymosin α1 in critical patients with tracheotomy. J South Med Univ 2006;26(11):128-129
85. Li P, Xu L-H, Zhang Q, et al. Treatment of drug-resistant Pseudomonas auruginosa pneumonia in elderly patients by using thymosin α1 with sulperazone. Chin J Nosocomial 2007;17:1271-1273
86. Mutchnick MG, Appleman HD, Chung HT, et al. Thymosin treatment of chronic hepatitis B: a placebo controlled trial. Hepatology 1991;14:409-415
87. Chan HL-Y, Tang J-L, Tam W, et al. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmacol Ther 2001;15:1899-1905 (Pubitemid 34014345)
88. Rasi G, Mutchnick MG, Di Virgilio D, et al. Combination low-dose lymphoblastoid interferon and thymosin α1 therapy in the treatment of chronic hepatitis B. J Viral Hepatitis 1996;3:191-196 (Pubitemid 126733934)
89. Liaw Y-F, Leung H, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update. Liver Int 2005;25:472-489
90. Sherman KE, Sjorgen M, Creager RL, et al. Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology 1998;27:1128-1135 (Pubitemid 28160500)
91. Gao T, Jiang WL, Wang WK, et al. Thymosin α1 treatment of severe chronic hepatitis. AASLD [abstract #687]. Hepatology 1998
92. Ma L-N, Chen Z-Y, Huang Y-L, et al. A clinical study of thymosin α1 as an auxiliary in treating spontaneous peritonitis in patients with liver cirrhosis. China J Hepatol 2001;15(3):225-230
93. Moody TW, Leyton J, Farah Z, et al. Thymosin α1 is a chemopreventive for lung adenoma formation in A/J mice. Cancer Lett 2000;155:121-127 (Pubitemid 30259125)
94. Schulof RS, Lloyd MJ, Cleary PA, et al. A randomized trial to evaluate the immunorestorative properties of synthetic thymosin α in patients with lung cancer. J Biol Resp Mod 1985;4:147-158 (Pubitemid 15101417)
95. Chretien PB. Thymic peptides in preclinical and clincal medicine. In: Maurer MR, Goldstein AL, editors, Munich: Zuckschwerdt Verlaq, 1997. p. 152-158
96. Garaci E, Lopez M, Bonsignore G, et al. Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin α1 and interferon-α 2a. Eur J Cancer 1995;13/14:2403-2405 (Pubitemid 26050586)
97. Salvati F, Rasi G, Portalone L, et al. Combined treatment with thymosin α1 and low dose interferon α after ifosfamide in non-small cell lung cancer: a Phase II controlled trial. Anticancer Res 1996;16:1001-1004 (Pubitemid 26182047)
98. Rasi G, Terzoli E, Izzo F, et al. Combined treatment with thymosin α1 and low dose interferon-α after dacarbazine in advanced melanoma. Melanoma Res 2000;10:189-192 (Pubitemid 30256882)
99. Lopez M, Carpano S, Cavaliere R, et al. Biochemotherapy with thymosin α1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects. Ann Oncol 1994;5:741-746 (Pubitemid 2151404)
100. Garaci E, Favalli C, Pica F, et al. Thymosin α1 from bench to bedside. Ann NY Acad Sci 2007;1112:226-234 (Pubitemid 47598679)
101. Grimm EA, Mazumder A, Zhang HZ, et al. Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982;155:1823-1841 (Pubitemid 12074218)
102. Mule JJ, Shu SA, Rosenberg SA. The antitumor efficacy of lymphokines-activated killer cells and recombinant interleukin-2 in vivo. J Immunol 1985;135:646-652 (Pubitemid 15012440)
103. Rosenberg SA, Mule JJ, Spiess PJ, et al. Regression of established pulmonary metastases and subcutaneous tumour mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 1985;161:1169-1188 (Pubitemid 15011332)
104. Camerini R, Mackiewicz A, Testori A, et al. A large first-line randomized dose-finding, phase II study on thymosin α (IFNα) compared to DTIC plus IFNα in stage IV melanoma. Tumor response and survival results. ASCO meeting Abstracts. 2007;25:8535
105. SciClone Reaches Agreement With FDA on Special Protocol Assessment for Phase 3 Thymalfasin Trial in Stage IV Melanoma, SciClone Press Release, November 17, 2008. Available from: http://phx. corporate-ir.net/phoenix.zhtml?c= 103184&p=irol-newsArticle&ID=1227051&highlight= [Last accessed 24 March 2009]
106. Yood MU, Quesenberry CP Jr, Guo D, et al. Incidence of hepatocellular carcinoma among individuals with hepatitis B virus infection identified using an automated data algorithm. J Viral Hepatol 2008;15(1):28-36 (Pubitemid 350243580)
107. Stefanini GF, Foschi FG, Castelli E, et al. Alpha-1-thymosin and transcatheter arterial chemoemobolization in hepatocellular carcinoma patients: a preliminary experience. Hepatogastroenterol 1998;45:209-215 (Pubitemid 28067555)
108. Gish R, Rustgi V, Nelson D, et al. Thymalfasin (thymosin α1) with trans arterial chemoembolization (TACE) in the treatment of adult patients with unresectable hepatocellular carcinoma: a Phase-II trial. Presented at Asia Pacific Association for the Study of Liver Diseases, 2009
109. Li ZS. HCC Patients treated with TACE combined with thymalfasin - one year follow up. Presented at: Millennium National Meeting on Viral Hepatitis in Shanghi, China, 2000
110. Cheng SQ, Wu MC, Chen H, et al. Transcatheter hepatic arterial chemoembolization and thymosin α1 in postoperative treatment of hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 2004;26(5):305-307
111. Cheng SQ, Wu MC, Chen H, et al. Hepatocellular carcinoma with tumor thrombi in the portal vein. A comparison of therapeutic effects by different treatments. Zhonghua Zhong Liu Za Zhi 2005;27(3):183-185
112. Cheng SQ, Wu MC, Chen H, et al. Anti-viral therapy using lamivudine and thymosin is helpful to prevent recurrence in hepatocellular carcinoma with coexisting active hepatitis B. Zhonghua Zhong Liu Za Zhi 2005;27(2):114-116
113. An TT, Liu XY, Fang J, et al. Primary assessment of treatment effect of thymosin α1 on chemotherapy-induced neurotoxicity. Chin J Cancer 2004;23(11):1428-1430
114. Chen J, Huang FL, Zheng XL, et al. Thymosin α1 (Tα1) positively alters quality of life (QoL) in chemotherapy of patients. ASCO. 2000;19:#2450A
115. Gupta S, Aggarwal S, Hguyen T. Accelerated spontaneous programmed cell death in DiGeorge syndrome. J Allergy Clin Immunol 1997;99(S 3):11
116. Lavastida MT, Goldstein AL, Daniels JC. Thymosin administration in autoimmune disorders. Thymus 1981;2:287-295 (Pubitemid 11157450)
117. Goya RG, Bolognani F. Homeostasis, thymic hormones, and aging. Gerontology 1999;45:174-178
118. Ershler W, Hebert J, Blow A, et al. Effect of thymosin α1 on specific antibody response and susceptibility to infection in young and aged mice. Int J Immunopharmacol 1985;7:465-471 (Pubitemid 15233466)
119. Ershler W, Moore A, Socinski M. Influenza and aging: age-related changes and the effects of thymosin on the antibody response to influenza vaccine. J Clin Immunol 1984;4:445-454 (Pubitemid 15217438)
120. Effros RB, Casillas A, Walford RL. The effect of thymosin α1 on immunity to influenza in aged mice. Aging: immunology and infectious disease. Mary Ann Liebert, Inc.; 1988;1:31-40
121. Gravenstein S, Duthie EH, Miller BA, et al. Augmentation of influenza antibody response in elderly men by thymosin α1. A double-blind placebo-controlled clinical study. J Am Geriatr Soc 1989;37:1-8 (Pubitemid 19032310)
122. McConnell L, Gravenstein S, Roecker E, et al. Augmentation of influenza antibody levels and reduction in attack rates in elderly subjects by thymosin α1. Gerontologist 1989;29:188A
123. Ershler WB, Gravenstein S, Geloo Z. Thymosin α1 as an adjunct to influenza vaccination in the elderly. rationale and trial summaries. Ann NY Acad Sci 2007;1112:375-384 (Pubitemid 47598685)